EMA begins safety review of bluebird gene therapy following AML case in related therapy

EMA begins safety review of bluebird gene therapy following AML case in related therapy

Source: 
Endpoints
snippet: 

The EMA officially announced early Friday that it will look into the safety of bluebird bio’s gene therapy Zynteglo, which is authorized in the EU to treat a rare blood condition, after an investigational gene therapy the company is developing for sickle cell led to a case of acute myeloid leukemia. Both Zynteglo and the gene therapy in development use the same viral vector.